Differences in prescribing between GPs: impact of the cooperation with pharmacists and impact of visits from pharmaceutical industry representatives.

BACKGROUND Community pharmacists, pharmaceutical industry and differences in prescribing between GPs. OBJECTIVE To explore the role of the pharmacists and pharmaceutical industry representatives. METHODS A cross-sectional survey was undertaken of 1434 GPs in The Netherlands in 2001. Prescribing indicators based on general practice guidelines were used to assess the quality of prescribing. Three constructs, based on survey questions, were used as possible determinants for the quality of prescribing: cooperation with the pharmacist; quality of the Pharmacotherapeutic audit meeting (PTAM); and the GP's attitude towards the pharmacist's role. Data were collected about the frequency of visits by pharmaceutical industry representatives. Responses from 324 solo GPs were analysed using multiple linear regression. RESULTS Response rate: 71%. For the 324 solo GPs the average score for the 20 prescribing indicators was 64% (SD 3.7). For the non-solo GPs this score was 65% (SD 3.8, P < 0.05). The differences between solo and group practices were: the number of visits from pharmaceutical industry representatives (5.7 versus 3.8 visits per month), full time GPs (93% versus 50%), the number of patients per GP (2151, SD 693 versus 1506, SD 742), and the presence of a GP trainer (21 versus 38%). Of the solo GPs, 4.6% are female, compared with 26% of the GPs in non-solo practices. The quality of prescribing in solo practices was not correlated with the GP's attitude towards the pharmacist's role, the way in which GPs cooperated with pharmacists or the quality of the PTAM. More frequent visits from pharmaceutical industry representatives was associated with a lower quality of prescribing. CONCLUSION There was a negative correlation between quality of prescribing by solo GPs and frequency of visits by pharmaceutical industry representatives. In day-to-day practice, no measurable effects of the cooperation between solo GP and pharmacist on the quality of prescribing were observed.

[1]  Rob Janknegt,et al.  Prescribing indicators , 2004, European Journal of Clinical Pharmacology.

[2]  L. Moore,et al.  Attitudes and behaviour of general practitioners and their prescribing costs: a national cross sectional survey , 2003, Quality & safety in health care.

[3]  Rob Janknegt,et al.  Prescribing indicators. Development and validation of guideline-based prescribing indicators as an instrument to measure the variation in the prescribing behaviour of general practitioners. , 2004, European journal of clinical pharmacology.

[4]  Sirpa Hartikainen,et al.  Use of medications and polypharmacy are increasing among the elderly. , 2002, Journal of clinical epidemiology.

[5]  Andrew D Oxman,et al.  Closing the gap between research and practice : an overview of systematic reviews of interventions to promote the implementation of research findings , 2011 .

[6]  C. Bradley,et al.  Primary care—opportunities and threats: developing prescribing in primary care , 1997, BMJ.

[7]  A. Wazana.  Physicians and the Pharmaceutical Industry: Is a Gift Ever Just a Gift? , 2000 .

[8]  L. Bero,et al.  Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes. , 2000, The Cochrane database of systematic reviews.

[9]  B Sibbald,et al.  Indicators of the appropriateness of long-term prescribing in general practice in the United Kingdom: consensus development, face and content validity, feasibility, and reliability. , 1998, Quality in health care : QHC.

[10]  C. Woodward,et al.  Collaboration between community pharmacists and family physicians: lessons learned from the Seniors Medication Assessment Research Trial. , 2003, Journal of the American Pharmacists Association : JAPhA.

[11]  J. Krska,et al.  Pharmacist-led medication review in patients over 65: a randomized, controlled trial in primary care. , 2001, Age and ageing.

[12]  T. Walley,et al.  Influences on GPs' decision to prescribe new drugs-the importance of who says what. , 2003, Family practice.

[13]  J. Hallas,et al.  Polypharmacy in general practice: differences between practitioners. , 1999, The British journal of general practice : the journal of the Royal College of General Practitioners.

[14]  J. Knottnerus,et al.  Changing relationships: attitudes and opinions of general practitioners and pharmacists regarding the role of the community pharmacist , 2003, Pharmacy World and Science.

[15]  Siobhan McCann,et al.  Perceived interprofessional barriers between community pharmacists and general practitioners: a qualitative assessment. , 2003, The British journal of general practice : the journal of the Royal College of General Practitioners.

[16]  J. Spencer,et al.  Pharmacy beyond the dispensary: general practitioners' views. , 1992, BMJ.

[17]  C. Bernsten,et al.  Improving the Well-Being of Elderly Patients via Community Pharmacy-Based Provision of Pharmaceutical Care , 2001, Drugs & aging.

[18]  R. Goeree,et al.  A randomized controlled trial of a pharmacist consultation program for family physicians and their elderly patients. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[19]  L. Shepstone,et al.  Does home based medication review keep older people out of hospital? The HOMER randomised controlled trial , 2005, BMJ : British Medical Journal.

[20]  A D Oxman,et al.  Educational outreach visits: effects on professional practice and health care outcomes. , 2007, The Cochrane database of systematic reviews.

[21]  L. Moore,et al.  Characteristics of general practitioners who frequently see drug industry representatives: national cross sectional study , 2003, BMJ : British Medical Journal.

[22]  M. Calnan,et al.  The reprofessionalisation of community pharmacy? An exploration of attitudes to extended roles for community pharmacists amongst pharmacists and General Practioners in the United Kingdom. , 2001, Social science & medicine.